Pfizer ’s Elranatamab Receives FDA and EMA Filing Acceptance

NEW YORK--(BUSINESS WIRE) February 22, 2023 -- Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the company’s Biologics License Application (BLA) for elranatamab, an...

https://www.drugs.com/nda/elranatamab_230222.html

Source: Drugs.com - New Drug Applications - February 22, 2023 Category: Drugs & Pharmacology Source Type: news

More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | New Drug Applications | Pfizer